IL274045B2 - Prodrugs of dantrolene and methods of using them - Google Patents
Prodrugs of dantrolene and methods of using themInfo
- Publication number
- IL274045B2 IL274045B2 IL274045A IL27404520A IL274045B2 IL 274045 B2 IL274045 B2 IL 274045B2 IL 274045 A IL274045 A IL 274045A IL 27404520 A IL27404520 A IL 27404520A IL 274045 B2 IL274045 B2 IL 274045B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- 26alkyl
- c1alkoc
- disease
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | DANTROLENE PRODRUGS AND METHODS OF USE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274045A IL274045A (en) | 2020-06-30 |
| IL274045B1 IL274045B1 (en) | 2023-05-01 |
| IL274045B2 true IL274045B2 (en) | 2023-09-01 |
Family
ID=64277793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274045A IL274045B2 (en) | 2017-10-20 | 2018-10-19 | Prodrugs of dantrolene and methods of using them |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11352347B2 (https=) |
| EP (2) | EP4574832A3 (https=) |
| JP (2) | JP7252963B2 (https=) |
| KR (1) | KR102652642B1 (https=) |
| CN (1) | CN111344286A (https=) |
| AU (2) | AU2018351494C1 (https=) |
| BR (1) | BR112020007858A2 (https=) |
| CA (1) | CA3079558A1 (https=) |
| CO (1) | CO2020006193A2 (https=) |
| ES (1) | ES3016835T3 (https=) |
| IL (1) | IL274045B2 (https=) |
| MA (1) | MA50403A (https=) |
| MX (2) | MX2020003400A (https=) |
| MY (1) | MY201417A (https=) |
| NZ (1) | NZ763377A (https=) |
| SG (1) | SG11202003452XA (https=) |
| UA (1) | UA127738C2 (https=) |
| WO (1) | WO2019079721A1 (https=) |
| ZA (1) | ZA202002779B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020007858A2 (pt) * | 2017-10-20 | 2020-10-27 | Eagle Research Labs Limited | composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto |
| SG11202104833YA (en) * | 2018-11-27 | 2021-06-29 | Eagle Res Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| IL296517A (en) * | 2020-04-10 | 2022-11-01 | Eagle Pharmaceuticals Inc | Methods of treating sars-cov-2 infections |
| US20230149364A1 (en) * | 2020-04-10 | 2023-05-18 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| WO2021207445A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
| WO2021207444A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating severe acute respiratory syndrome |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) * | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20080206332A1 (en) | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| EP2219605B1 (en) | 2007-10-09 | 2015-08-19 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| FR2944525B1 (fr) | 2009-04-17 | 2011-06-24 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| EP2765860B1 (en) | 2011-10-13 | 2016-08-17 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| CN105209030B (zh) | 2013-03-15 | 2018-06-12 | 罗莎琳德富兰克林医科大学 | 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物 |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| CA2946253C (en) | 2013-05-06 | 2022-08-09 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| EP2994132A4 (en) | 2013-05-08 | 2016-11-16 | Univ Howard | COMPOSITIONS AND METHOD FOR TREATING NEURONAL ISCHEMIC REPERFUSION DAMAGE |
| HUP1300720A2 (hu) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| JPWO2015182625A1 (ja) | 2014-05-26 | 2017-06-08 | 国立大学法人京都大学 | Ｒａｓ活性阻害薬及びその用途 |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| CN108366963A (zh) | 2015-10-20 | 2018-08-03 | B.布劳恩梅尔松根股份公司 | 包含丹曲林的水性组合物 |
| BR112020007858A2 (pt) * | 2017-10-20 | 2020-10-27 | Eagle Research Labs Limited | composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto |
| SE542780C2 (en) | 2018-09-15 | 2020-07-07 | Coloreel Group AB | A system and method for in-line treatment of thread |
-
2018
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/pt active Search and Examination
- 2018-10-19 MA MA050403A patent/MA50403A/fr unknown
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/ja active Active
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 EP EP25160825.3A patent/EP4574832A3/en active Pending
- 2018-10-19 ES ES18801102T patent/ES3016835T3/es active Active
- 2018-10-19 AU AU2018351494A patent/AU2018351494C1/en active Active
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/es unknown
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/ko active Active
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/zh active Pending
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en not_active Ceased
- 2018-10-19 NZ NZ763377A patent/NZ763377A/en unknown
- 2018-10-19 EP EP18801102.7A patent/EP3697779B1/en active Active
- 2018-10-19 MY MYPI2020001973A patent/MY201417A/en unknown
- 2018-10-19 UA UAA202002979A patent/UA127738C2/uk unknown
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/es unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/es unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US12269815B2/en active Active
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/ja active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113B2/en active Active
-
2024
- 2024-10-17 US US18/918,855 patent/US20250145593A1/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| SNYDER, HARRY R., ET AL., 1-[5-ARYLFURFURYLIDENE) AMINO] HYDANTOINS. A NEW CLASS OF MUSCLE RELAXANTS., 31 December 1967 (1967-12-31) * |
| WESSELS, F. L., K. O. ELLIS, AND R. L. WHITE JR., SYNTHESIS AND SKELETAL MUSCLE RELAXANT ACTIVITY OF 3?(AMINOACYL)?1?[[[5?(SUBSTITUTED PHENYL)?2?FURANYL] METHYLENE] AMINO]?2, 4?IMIDAZOLIDINEDIONES., 31 December 1981 (1981-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274045B2 (en) | Prodrugs of dantrolene and methods of using them | |
| US11679095B2 (en) | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | |
| Bialer | Why are antiepileptic drugs used for nonepileptic conditions? | |
| US20250312308A1 (en) | Methods of treating neurological and psychiatric disorders | |
| Sharma et al. | Fingolimod (FTY720): First approved oral therapy for multiple sclerosis | |
| JP2007516227A5 (https=) | ||
| US6369052B1 (en) | Combination of huperzine and nicotinic compounds as a neuroprotective agent | |
| EP4306167B1 (en) | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | |
| WO2012012347A3 (en) | Methods of intravenous administration of glyburide and other drugs | |
| US9855238B2 (en) | Compositions comprising 15-HEPE and methods of using the same | |
| US11981617B2 (en) | Ketamine pamoate and use thereof | |
| JP2019533642A5 (https=) | ||
| JP2015180673A (ja) | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 | |
| JP2010505961A5 (https=) | ||
| TW513304B (en) | Use of an alkanoyl L-carnitine or a pharmacologically acceptable salt thereof for the therapeutic treatment or prophylaxis of glutamate-mediated disturbances or diseases | |
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| WO2023040716A1 (zh) | 烟酰胺腺嘌呤二核苷酸在治疗阿霉素诱导的心脏毒性中的应用 | |
| Stober et al. | Correlation of cardiac arrhythmias with brainstem compression in patients with intracerebral hemorrhage. | |
| WO2010005581A4 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) | |
| WO2017115873A1 (ja) | アルツハイマー病の予防及び／又は治療剤 | |
| JP2025506252A (ja) | 鎮痛及び／又は鎮痒機能を有する医薬組成物及びその使用 | |
| US9789092B2 (en) | Biotin for use in treating X-linked adrenoleukodystrophy | |
| US20200306222A1 (en) | Dosing Regimen of Siponimod | |
| JP2021524855A5 (https=) | ||
| Sharma et al. | Comparison of lignocaine and fentanyl for attenuation of cardiovascular response during laryngoscopy and tracheal intubation in cardiac surgery patients |